study_id,trial_name,registry_id,country_multicenter,design,background_therapy,timepoint_weeks,estimand_used,analysis_population,arm_id,treatment_name,dose_mg,frequency,n_randomized,n_analyzed,mean_change_hba1c,measure_type,dispersion_type,dispersion_value,notes,source_location
SURPASS-2,SURPASS-2,NCT03987919,"Multinational, multicenter (128 sites)","Phase 3; randomized; open-label; active-controlled; parallel-group","Metformin (>=1500 mg/day) add-on",40,"treatment-regimen (reported unless stated otherwise)","mITT (received >=1 dose)",SURPASS2_TIRZ5,tirzepatide_5,5,once_weekly,NA,470,-2.01,"estimated mean (LS mean)","none",NA,"Primary endpoint is HbA1c change baseline->Week 40; reported results are treatment-regimen estimand unless stated otherwise. Arm n is mITT baseline table count; randomized per-arm n not explicitly stated in provided snippet (total randomized 1879; total mITT 1878).","NEJM full text p.503 Abstract (HbA1c change); NEJM Table 1 baseline mITT counts p.507"
SURPASS-2,SURPASS-2,NCT03987919,"Multinational, multicenter (128 sites)","Phase 3; randomized; open-label; active-controlled; parallel-group","Metformin (>=1500 mg/day) add-on",40,"treatment-regimen (reported unless stated otherwise)","mITT (received >=1 dose)",SURPASS2_TIRZ10,tirzepatide_10,10,once_weekly,NA,469,-2.24,"estimated mean (LS mean)","none",NA,"Same endpoint/estimand notes as above.","NEJM full text p.503 Abstract (HbA1c change); NEJM Table 1 baseline mITT counts p.507"
SURPASS-2,SURPASS-2,NCT03987919,"Multinational, multicenter (128 sites)","Phase 3; randomized; open-label; active-controlled; parallel-group","Metformin (>=1500 mg/day) add-on",40,"treatment-regimen (reported unless stated otherwise)","mITT (received >=1 dose)",SURPASS2_TIRZ15,tirzepatide_15,15,once_weekly,NA,470,-2.30,"estimated mean (LS mean)","none",NA,"Same endpoint/estimand notes as above.","NEJM full text p.503 Abstract (HbA1c change); NEJM Table 1 baseline mITT counts p.507"
SURPASS-2,SURPASS-2,NCT03987919,"Multinational, multicenter (128 sites)","Phase 3; randomized; open-label; active-controlled; parallel-group","Metformin (>=1500 mg/day) add-on",40,"treatment-regimen (reported unless stated otherwise)","mITT (received >=1 dose)",SURPASS2_SEMA1,semaglutide_1,1,once_weekly,NA,469,-1.86,"estimated mean (LS mean)","none",NA,"Comparator arm; same endpoint/estimand notes as above.","NEJM full text p.503 Abstract (HbA1c change); NEJM Table 1 baseline mITT counts p.507"